Press Releases

Year

September 19, 2022

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

SAN CARLOS, Calif. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common

September 12, 2022

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Top-line Phase 2b results expected in the second half of 2023 SAN CARLOS, Calif. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has

September 9, 2022

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif. , Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and

August 4, 2022

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

July 25, 2022

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

SAN CARLOS, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L.

May 6, 2022

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif. , May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

March 1, 2022

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the

February 1, 2022

Allakos to Host Investor Day on February 15

– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related

Investors

Press Releases

(Common Stock)

Investor Toolkit